Intriguingly, increased pro-tumorigenic factor COX-2 in TME might contribute to the attenuated therapeutic responses of breast cancer to ruxolitinib and promote tumor progresses [73, 74]. The gene discussed is PTGS2; the disease is breast carcinoma.